drugset / Trial / NCT02870036

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

NCT02870036

Phase 1 Unknown 243 enrolled Haihe Biopharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with advanced solid tumor or advanced/metastatic colorectal cancer.

Timeline

Start
2016-10
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule
Subject Simmitecan Small molecule
Subject Thalidomide Other / unclassified
Subject fluorouracil Small molecule

Indications